| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 05/24/2000 | EP1002132A1 90 human secreted proteins |
| 05/24/2000 | EP1002108A2 Use of mhc class ii ligands as adjuvant for vaccination and of lag-3 in cancer treatment |
| 05/24/2000 | EP1002099A1 Synaptojanin isoform |
| 05/24/2000 | EP1002091A1 Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue |
| 05/24/2000 | EP1002082A2 Transcriptional silencer protein nrf |
| 05/24/2000 | EP1002072A1 Human semaphorin e and polynucleotides encoding it |
| 05/24/2000 | EP1002070A1 Human atp-binding cassette transport protein |
| 05/24/2000 | EP1002069A1 Peptides containing the motif igd and their use as cell migration modulators |
| 05/24/2000 | EP1001986A2 Pharmaceuticals for modulating hormone responsiveness |
| 05/24/2000 | EP1001985A1 Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo |
| 05/24/2000 | EP1001984A1 NOVEL ESTROGEN RECEPTOR $g(b) AND ISOFORMS |
| 05/24/2000 | EP1001983A1 NOVEL ESTROGEN $g(b) RECEPTOR AND ISOFORMS |
| 05/24/2000 | EP1001979A1 Cyclic azapeptides with angiogenic effect |
| 05/24/2000 | EP1001977A2 Radiolabeled peptides for the diagnosis and treatment of breast and prostate tumors and metastases of such tumors |
| 05/24/2000 | EP1001974A1 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 05/24/2000 | EP1001973A1 Compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 05/24/2000 | EP1001972A1 Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 05/24/2000 | EP1001957A1 Macrolides with antitumor activity |
| 05/24/2000 | EP1001951A1 Thiazole derivatives, method for their production and use |
| 05/24/2000 | EP1001946A1 QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56?1ck TYROSINE KINASES |
| 05/24/2000 | EP1001945A1 QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56?lck TYROSINE KINASES |
| 05/24/2000 | EP1001936A1 Bis -acridinecarboxamide having anti-tumor activity |
| 05/24/2000 | EP1001930A2 N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases |
| 05/24/2000 | EP1001927A2 Novel polyamine analogues as therapeutic and diagnostic agents |
| 05/24/2000 | EP1001811A1 Nanoscale particles having an iron oxide-containing core enveloped by at least two shells |
| 05/24/2000 | EP1001808A1 Adjuvant compositions for vaccines |
| 05/24/2000 | EP1001807A1 Adoptive immunotherapy utilizing heat shock/stress protein-peptide complexes for prevention/treatment of cancer or infectious diseases |
| 05/24/2000 | EP1001806A1 Cellular vesicle called ''exosome'', preparation and use thereof in immune stimulation |
| 05/24/2000 | EP1001800A2 Biologically active peptides with reduced toxicity in animals and a method for preparing same |
| 05/24/2000 | EP1001799A1 Pharmaceutical composition containing peptichemio |
| 05/24/2000 | EP1001797A1 Soya extract, process for its preparation and pharmaceutical composition |
| 05/24/2000 | EP1001785A1 Use of colchinol derivatives as vascular damaging agents |
| 05/24/2000 | EP1001781A2 Use of taurolidine or taurultam for the manufacture of a medicament for the prevention of metastases |
| 05/24/2000 | EP1001769A4 Soluble prodrugs of paclitaxel |
| 05/24/2000 | EP1001769A1 Soluble prodrugs of paclitaxel |
| 05/24/2000 | EP1001756A1 Synergistically acting compositions for selectively combating tumor tissue |
| 05/24/2000 | EP1001755A2 Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
| 05/24/2000 | EP1001753A1 Low dosed 15-desoxyspergualine preparations |
| 05/24/2000 | EP0931083A4 Process for producing ecteinascidin compounds |
| 05/24/2000 | EP0815095B1 10-deacetylbaccatine iii and 10-deacetyl 14 beta-hydroxybaccatine iii derivatives, a process for the preparation thereof and pharmaceutical compositions containing them |
| 05/24/2000 | EP0787135B1 Water-soluble epipodophyllotoxin derivatives, preparation method therefor, and use thereof as a drug and for treating cancer |
| 05/24/2000 | EP0725629B1 Liposomal defensins |
| 05/24/2000 | EP0720620B1 Glutathione analogs and paralog panels comprising glutathione mimics |
| 05/24/2000 | EP0679156B1 Process for the preparation of 10-desacetoxybaccatin III and 10-desacetoxytaxol and derivatives thereof |
| 05/24/2000 | CN1254378A Adneovirus-mediated intratumoral delivery of angiogenesis antagonist for treatment of tumors |
| 05/24/2000 | CN1254376A 端粒酶逆转录酶 Telomerase reverse transcriptase |
| 05/24/2000 | CN1254346A Calcitonin receptor-binding peptides |
| 05/24/2000 | CN1254345A Serine protease inhibitors |
| 05/24/2000 | CN1254344A Estrogenic 10-Noradnrost-17-one derivatives with aromatic B-ring |
| 05/24/2000 | CN1254343A Pregnane 3,20 diol mono- and di-sulphates |
| 05/24/2000 | CN1254342A Pharmaceutically acceptable salts of 5 alpha-pregnan-3-beta, 16 alpha-diol-20-one 3-sulfate useful as progestins and CNS disorders |
| 05/24/2000 | CN1254341A Pharmaceutically accpetable salts of 3-hydroxy-estr-5-(10)-en-17-one 3-sulphate active as estrogens |
| 05/24/2000 | CN1254339A Ethylene glycol esters of monohydrobenzoporphyrin derivatives as photoactive agents |
| 05/24/2000 | CN1254337A N-hydroxy 4-sulfonyl butyramide compounds |
| 05/24/2000 | CN1254293A Targeted therapeutic delivery of vitamin D compounds |
| 05/24/2000 | CN1254290A Genes coding proteins for early liver development and their use in diagnosing and treating liver disease |
| 05/24/2000 | CN1254283A Pregnan-3-ol-20-ones |
| 05/24/2000 | CN1254282A Benzimidazole-2-carbamates for treatment of viral infections and cancer |
| 05/24/2000 | CN1254281A HIV and cancer treatment |
| 05/24/2000 | CN1254279A Methods and compositions for treatment of ovarian cancer |
| 05/24/2000 | CN1254278A Pharmaceutical injection solution containing taxol |
| 05/24/2000 | CN1253948A Substituted tricyclic compound |
| 05/24/2000 | CN1253813A Medicine composition for curing angiocardiopathy and cerebrovascular disease and its preparation method |
| 05/24/2000 | CN1052733C Immuno-stimulatory monoclonal antibodies |
| 05/24/2000 | CN1052732C Process for preparing anti-cancer synergist taking IL-2 as main component made from pig blood, sheep blood, pig spleen and sheep spleen |
| 05/24/2000 | CN1052731C Compounds with growth hormone releasing properties |
| 05/24/2000 | CN1052648C Repellent analgesic ointment for cancer or tumor |
| 05/23/2000 | US6066747 Process for the preparation of 9-desoxotaxanes |
| 05/23/2000 | US6066742 Intermediates for the preparation of duocarmycin SA and derivatives thereof, and process for the production of the intermediates |
| 05/23/2000 | US6066730 Boronic ester and acid compounds, synthesis and uses |
| 05/23/2000 | US6066720 Modified oligonucleotides, their preparation and their use |
| 05/23/2000 | US6066668 Formulations and methods of reducing toxicity of antineoplastic agents |
| 05/23/2000 | US6066665 Combination of cis-4-hydroxy-L-proline and N-methyl-cis-4-hydroxy-L-proline for use as a therapeutic agent, in particular in cancer treatment |
| 05/23/2000 | US6066662 Use in control or prevention of rheumatoid arthritis and osteoarthritis or in the treatment of invasive tumours, atherosclerosis or multiple sclerosis |
| 05/23/2000 | US6066645 Administering an effective amount of the protective agent to a patient receiving one or more antineoplastic agents; compounds useful as protective agents have either a sulfhydryl moiety or are reducible disulfides |
| 05/23/2000 | US6066633 Prevent tissue degradation |
| 05/23/2000 | US6066625 Enzyme inhibitor; modulators of gene expression |
| 05/23/2000 | US6066624 Gene therapy for solid tumors using adenoviral vectors comprising suicide genes and cytokine genes |
| 05/23/2000 | US6066616 Administering octreotide |
| 05/23/2000 | US6066319 Administering membrane attack complex (mac) transmembrane channel forming agent which is an antibody simultaneously therewith an effective amount of a therapeutic or diagnostic agent |
| 05/23/2000 | CA2048367C Solid oral forms of application containing ifosfamide as active substance |
| 05/18/2000 | WO2000028554A1 Products and methods for brachytherapy |
| 05/18/2000 | WO2000028323A1 Methods for identifying modulators of bs69 activity |
| 05/18/2000 | WO2000028059A1 Adenovirus-mediated gene therapy |
| 05/18/2000 | WO2000028045A2 Human hydrolase proteins |
| 05/18/2000 | WO2000028039A2 Identification of senv genotypes |
| 05/18/2000 | WO2000028029A2 Cell surface glycoproteins |
| 05/18/2000 | WO2000028027A2 Corticosteroid synthesis-associated genes |
| 05/18/2000 | WO2000028025A1 Pholasin |
| 05/18/2000 | WO2000028024A1 htfIIIA HUMAN GENE AND CODED hTFIIIA PROTEIN |
| 05/18/2000 | WO2000028022A1 Pge synthase and methods and means for modulating its activity |
| 05/18/2000 | WO2000028016A1 T cells specific for target antigens and methods and vaccines based thereon |
| 05/18/2000 | WO2000028010A2 The genetic determination of genes and its use for the prophylaxis and therapy of diseases |
| 05/18/2000 | WO2000028004A1 Virus vectors and methods of making and administering the same |
| 05/18/2000 | WO2000028001A1 Modified exosomes and uses |
| 05/18/2000 | WO2000027883A2 A method of treating tumors using fas-induced apoptosis |
| 05/18/2000 | WO2000027879A1 Platelet-derived growth factor d, dna coding therefor, and uses thereof |
| 05/18/2000 | WO2000027874A2 Nucleic acids encoding transferrin receptor-like proteins and products related thereto |
| 05/18/2000 | WO2000027866A1 Inhibition of angiogenesis by high molecular weight kininogen and peptide analogs thereof |
| 05/18/2000 | WO2000027864A1 CHROMOSOME 17p-LINKED PROSTATE CANCER SUSCEPTIBILITY GENE |